KUALA LUMPUR, Oct 19 (Bernama) — InterVenn, a San Francisco based biotechnology company innovating precision medicine and diagnostic products using next-generation mass spectrometry coupled to a proprietary artificial Intelligence/machine learning-based data processing engine, has announced a collaboration with Agilent Technologies, a leading provider of bio-analytical and scientific instrumentation.
This strategic partnership gathers the strength of both parties to develop cutting edge precision diagnostic tools by investigating targeted glycoproteomic biomarkers for diseases such as cancer.
